PB 9 of 2020

National Health (Originator Brand) Amendment Determination 2020 (No. 1)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated 29 January 2020

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

1 Name of Determination

 (1) This Determination is the National Health (Originator Brand) Amendment Determination 2020 (No. 1).

(2) This Determination may also be cited as PB 9 of 2020.

2 Commencement

  This Determination commences on 1 February 2020.

3 Amendments to PB 100 of 2015

  Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1 Amendments

(section 3)

[1]  Schedule 1, (table item 80)

Repeal the items:

80

Exemestane

Aromasin

 

 

80A

Ezetimibe

Ezetrol

 

 

80B

Ezetimibe and rosuvastatin

Rosuzet Composite Pack

 

 

80C

Ezetimibe with simvastatin

Vytorin

 

 

Substitute:

80

Exemestane

Aromasin

 

 

80A

Ezetimibe

Ezetrol

 

 

80B

Ezetimibe and rosuvastatin

Rosuzet Composite Pack

 

 

80C

Ezetimibe with atorvastatin

Atozet

 

 

80D

Ezetimibe with simvastatin

Vytorin

 

 

[2]  Schedule 1, (after table item 228)

Insert:

228A

Tiotropium

Spiriva

Spiriva Respimat